3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
10
Breast Neoplasms
6
Triple Negative Breast Neoplasms
3
Sarcoma
3
Fallopian Tube Neoplasms
3
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Breast Cancer Metastatic
2
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
SCLC, Extensive Stage
1
Recurrence
1
Platinum-sensitive Relapsed Ovarian Cancer
1
Osteosarcoma
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Kenny-Caffey syndrome, Type 1
1
Her-2 Negative Breast Cancer
1
Glioblastoma
1
Fludzoparib" and Anti-angiogenic
1
Female Breast Cancer Patients
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
1
Interventions
Methotrexate
21
Ifosfamide
21
Cyclophosphamide
19
Doxorubicin
17
Cisplatin
14
Filgrastim
13
Gemcitabine
12
Etoposide
11
Leucovorin
9
apatinib
8
fludarabine
7
glucarpidase
6
Vincristine
6
Temozolomide
6
Radiotherapy
6
Nivolumab
6
Neoadjuvant Therapy
6
Drug Therapy
6
Carboplatin
6
regorafenib
5
cabozantinib
5
Zoledronic Acid
5
Topotecan
5
Mesna
5
Irinotecan
5
Granulocyte Colony-Stimulating Factor
5
Docetaxel
5
pembrolizumab
4
pegfilgrastim
4
camrelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Osteosarcoma
×
fluzoparib
×
Clear all
NCT06074692
2023-10-31
PRIMA
Ruijin Hospital
Phase 2
Recruiting
86 enrolled